BioSpecifics Technologies (NASDAQ:BSTC) released its quarterly earnings results on Friday. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.14, MarketWatch Earnings reports. The firm had revenue of $8.17 million for the quarter, compared to the consensus estimate of $7.19 million. BioSpecifics Technologies had a return on equity of 19.59% and a net margin of 49.78%.

Shares of BSTC stock traded up $0.46 during midday trading on Friday, hitting $57.96. The company had a trading volume of 42,537 shares, compared to its average volume of 39,547. BioSpecifics Technologies has a 52-week low of $38.05 and a 52-week high of $66.21. The company has a market capitalization of $463.15 million, a P/E ratio of 34.09 and a beta of 1.48.

A number of research analysts recently issued reports on the company. HC Wainwright set a $72.00 price target on BioSpecifics Technologies and gave the stock a “buy” rating in a research note on Thursday, November 1st. BidaskClub downgraded BioSpecifics Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, September 22nd. Finally, Zacks Investment Research downgraded BioSpecifics Technologies from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 10th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $69.33.

In other BioSpecifics Technologies news, major shareholder Of Edwin H. Wegman Estate sold 7,935 shares of BioSpecifics Technologies stock in a transaction that occurred on Saturday, September 1st. The stock was sold at an average price of $37.53, for a total value of $297,800.55. Following the transaction, the insider now directly owns 1,005,128 shares in the company, valued at approximately $37,722,453.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul Gitman sold 1,000 shares of BioSpecifics Technologies stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $57.64, for a total value of $57,640.00. Following the completion of the transaction, the director now owns 20,000 shares in the company, valued at $1,152,800. The disclosure for this sale can be found here. Insiders sold a total of 177,952 shares of company stock worth $8,128,384 over the last quarter. Company insiders own 21.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “BioSpecifics Technologies (BSTC) Issues Earnings Results, Beats Estimates By $0.14 EPS” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2018/11/10/biospecifics-technologies-bstc-issues-earnings-results-beats-estimates-by-0-14-eps.html.

About BioSpecifics Technologies

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names.

Featured Story: What Is An Exchange-Traded Fund (ETF)?

Earnings History for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.